
T2 BIOSYSTEMS NEW DL-,001
Action · US89853L3024 · TTOO · A3EU63 (XNCM)
0,13 EUR
06.06.2025 19:43
Cours actuels de T2 BIOSYSTEMS NEW DL-,001
Bourse | Ticker | Devise | Dernier échange | Cours | Variation journalière |
---|---|---|---|---|---|
![]() NASDAQ |
TTOO
|
USD
|
06.06.2025 19:43
|
0,15 USD
| 0,16 USD
-3,23 %
|
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
-0,49 % | -6,36 % | -7,64 % | 3,33 % | -72,74 % | -96,69 % | -100,00 % |
Profil de l'entreprise pour T2 BIOSYSTEMS NEW DL-,001 Action
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Données de l'entreprise
Nom T2 BIOSYSTEMS NEW DL-,001
Société T2 Biosystems, Inc.
Symbole TTOO
Site web
https://www.t2biosystems.com
Marché d'origine
Frankfurt

WKN A3EU63
ISIN US89853L3024
Type de titre Action
Secteur Healthcare
Industrie Medical - Diagnostics & Research
PDG Mr. Craig R. Jalbert CIRA
Pays États-Unis d'Amérique
Devise EUR
Employés 0,1 T
Adresse 101 Hartwell Avenue, 02421 Lexington
Date d'introduction en bourse 2014-08-07
Symboles boursiers
Nom | Symbole |
---|---|
Frankfurt | 3T2.F |
NASDAQ | TTOO |
Autres actions
Les investisseurs qui détiennent T2 BIOSYSTEMS NEW DL-,001 ont également les actions suivantes dans leur portefeuille :
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles.
Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.